PART 01: Executive summary • Highlights PART 02: Scope of the report • Market overview • Top-vendor offerings PART 03: Market research methodology • Research methodology • Economic indicators PART 04: Introduction • Key market highlights PART 05: Plasma therapeutics: An overview • Components of blood plasma • Derivation of various plasma therapeutics PART 06: Global plasma therapeutics market • Market overview • Market size and forecast PART 07: Plasma fractionation market • Overview • Market size and forecast • Market players PART 08: Albumin: An overview • Types of albumin • Albumin in human body • Clinical uses PART 09: Pipeline portfolio PART 10: Global albumin market PART 11: Market landscape • Global human albumin market • Five forces analysis PART 12: Market segmentation by application • Replacement therapy • Drug formulation and delivery • Vaccine ingredients • Others PART 13: Geographical segmentation • Global human albumin market by geographical segmentation 2015-2020 • Human albumin market in APAC • Human albumin market in Americas • Human albumin market in EMEA PART 14: China albumin market • Plasma therapeutics market in China • Human albumin market in China PART 15: Market drivers • High demand for human albumin in China • Exploitation of new therapeutic indications • Increase in production capacity PART 16: Impact of drivers PART 17: Market challenges • High cost of therapy • Spread of pathogenic contaminants • High regulations in the market PART 18: Impact of drivers and challenges PART 19: Market trends • Novel technologies for albumin-based drug development • Rise in non-therapeutic applications • Increased development of recombinant albumin PART 20: Vendor landscape • Competitive scenario • Market analysis 2015 • CSL Behring • Grifols • Baxalta • Octapharma • Kedrion • Other prominent vendors PART 21: Appendix • List of abbreviations PART 22: Explore Technavio List of Exhibits Exhibit 01: Product offerings Exhibit 02: Blood plasma composition Exhibit 03: Plasma proteins composition by percentage share Exhibit 04: Total number of plasma donations in US 2010-2014 Exhibit 05: Projected global YoY growth and fractionation capacity of manufacturing units (millions of liter/annum) Exhibit 06: Process of derivation of AAT from plasma Exhibit 07: Global plasma therapeutics market 2015-2020 ($ billions) Exhibit 08: Segmentation of plasma-derived products on revenue 2015 Exhibit 09: Global plasma fractionation market 2015-2020 ($ billions) Exhibit 10: Line of treatment of albumin in various diseases Exhibit 11: Pipeline portfolio: Albumin-based therapeutics Exhibit 12: Segmentation of global albumin market Exhibit 13: Global human albumin market 2015-2020 ($ billions) Exhibit 14: Global human albumin market 2015-2020 (tons) Exhibit 15: Five forces analysis Exhibit 16: Segmentation of human albumin market based on application Exhibit 17: Segmentation of global human albumin market based on geography 2015 Exhibit 18: Human albumin market revenue by geography 2015-2020 ($ billions) Exhibit 19: Human albumin market by geography 2015-2020 Exhibit 20: Human albumin market in APAC 2015-2020 ($ billions) Exhibit 21: Albumin market in China in global albumin market 2015 Exhibit 22: Human albumin market in Americas 2015-2020 ($ billions) Exhibit 23: Albumin market in US 2015 Exhibit 24: Human albumin market in EMEA 2015-2020 ($ millions) Exhibit 25: Global human albumin market: YoY growth and revenue based on geography 2015-2020 Exhibit 26: Segmentation of various plasma products 2015 Exhibit 27: Plasma therapeutics market in China 2015-2020 ($ billions) Exhibit 28: Human albumin market in China 2015-2020 ($ billions) Exhibit 29: Domestic and imported albumin in China 2015 Exhibit 30: Impact of drivers Exhibit 31: Impact of drivers and challenges Exhibit 32: CSL Behring: Segmentation by revenue 2015 Exhibit 33: CSL Behring: YoY revenue and growth rate of albumin products 2013-2015 ($ millions) Exhibit 34: CSL Behring: Key takeaways Exhibit 35: Grifols: YoY growth rate and revenue of bioscience segment 2013-2015 ($ billions) Exhibit 36: Grifols: Key takeaways Exhibit 37: Baxalta: Segmentation by revenue 2015 Exhibit 38: Baxalta: YoY revenue comparison of Biotherapeutics segment 2013-2015 ($ millions) Exhibit 39: Baxalta: Geographic segmentation of BioTherapeutics 2015 Exhibit 40: Baxalta: Key takeaways Exhibit 41: Octapharma: Key takeaways Exhibit 42: Kedrion: Key takeaways

CSL Behring, Grifols, Baxalta, Octapharma, Kedrion, AADi, Ablynx, Albumedix, Ampio Pharmaceuticals, Azaya Therapeutics, Beijing Tiantan, Biotest, Bristol-Myers Squibb, Celgene, ConjuChem, GSK, Hebei Changshan Biochem Pharma, HiMedia Laboratories, Hualan Biological Engineering, InVittria, MedxBio, Merck, Mitsubishi Tanabe Pharma, NantBioScience, Novo Nordisk, Novozymes, Shanghai RAAS Blood Products, Sucampo Pharmaceuticals, Teva Pharmaceuticals, Thermo Fisher Scientific, Tianjin SinoBiotech & Beijing Bio-Fortune, Ventria Bioscience, Yoshitomi Pharmaceutical.